Status:
TERMINATED
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as f...
Detailed Description
The study prematurely discontinued on January 26, 2011 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of extensive stage disease Small Cell Lung Cancer (SCLC), with tumor biopsy sample required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Total IGF-1 \> or = 120 ng/ml
Exclusion
- Any prior systemic therapy for Small Cell Lung Cancer (SCLC)
- HbA1c \> or = 5.7%
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00977561
Start Date
April 1 2010
End Date
October 1 2011
Last Update
February 25 2013
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Washington D.C., District of Columbia, United States, 20007-2197
2
Pfizer Investigational Site
Washington D.C., District of Columbia, United States, 20007
3
Pfizer Investigational Site
Marrero, Louisiana, United States, 70072
4
Pfizer Investigational Site
Metairie, Louisiana, United States, 70006